What is Eclipse BioInnovations?
Founded in 2017, Eclipse BioInnovations operates at the intersection of next-generation sequencing and computational biology. The company specializes in mapping the RNA-interactome, providing high-resolution insights that are essential for modern drug discovery and molecular diagnostics. Through its proprietary genomics platform, Eclipse delivers a suite of advanced products that enable researchers to decode complex RNA interactions. This technological edge has positioned the firm as a vital partner for organizations seeking to push the boundaries of medical breakthroughs, effectively bridging the gap between raw genomic data and actionable scientific intelligence.
How much funding has Eclipse BioInnovations raised?
Eclipse BioInnovations has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Eclipse BioInnovations
PPP
Public-Private Partnership
What's next for Eclipse BioInnovations?
With this late-stage financing, Eclipse BioInnovations is strategically positioned to scale its operational capacity and expand its product portfolio. The company is expected to focus on enhancing its computational biology solutions, which are increasingly in demand as the biopharma industry shifts toward RNA-based therapeutics. By scaling its infrastructure and deepening its market penetration, Eclipse aims to standardize its RNA genomics tools, ensuring they remain the gold standard for high-resolution interactome mapping. Future growth will likely be driven by strategic partnerships and the continued refinement of its sequencing technologies to meet the evolving needs of the global scientific community.
See full Eclipse BioInnovations company page
